News and Comments

Another Durable Botulinum Toxin with Many Advantages Over Botox

  Thursday, October 29, 2015

Another Durable, Botulinum Toxin with Many Advantages More...

Cytokinetics Heart Failure Drug Worked

  Tuesday, October 27, 2015

POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE More...

URGENT BREAKING NEWS

  Thursday, October 22, 2015

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease.  More...

The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


 More...

Sarepta Versus Biomarin: Trying to make an Educated Guess

  Monday, October 19, 2015

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to decide upon reviewing Biomarin’s (BMRN) Duchenne muscular dystrophy (DMD) drug Drisapersen a few weeks earlier than reviewing Sarepta (SRPT) DMD drug Eteplirsen.  More...

Incyte And Merck Agree to Expand Their agreement Regarding their Immunotherapy Combination Drugs

  Tuesday, October 13, 2015

 More...

Yesterday Market Performance Brings Back Hope in Normalcy. Compugen Announced Some Encouraging News.

  Thursday, October 08, 2015

Stories From Yesterday Market More...

XOMA: A New Chance for Resurrection?

  Friday, October 02, 2015
  • - Exclusively licenses global rights to its (TGFb) antibody program to Novartis 
  •  More...

EXELIXIS: The Stream Of Good News Continues to Flow

  Monday, September 28, 2015

Exelixis (EXEL) announced positive results from the METEOR Phase 3 Pivotal Trial of Cabozantinib in advanced renal cell carcinoma, which was presented at the European Cancer Congress 2015. In the study, Cabozantinib met the primary endpoint of improving progression-free survival as compared to Evorulimus.  More...

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of A Promising Glaucoma Drug

  Thursday, September 17, 2015

Aerie Pharmaceuticals (AERI), which is specialized in glaucoma treatments reported successful results of its second Phase 3 trial for Rhopressa™ — a novel once-daily, triple-action eye drops for glaucoma.   More...


Recent Postings


Archive


Tags

galapagos (GLPG) Biocryst (BCRX) Herceptin NANTKWEST (NK) Auspex (ASPX) Vitae Pharmaceuticals (VTAE) Rapamune Galena (GALE) Mirati Therapeutics (MRTX) Valeant Pharmaceuticals International (VRX) SYNTA (SNTA) Ziofpharm (ZIOP) ARGOS (ARGS) Regeneron (REGN) Ridaforolimus JUNO (JUNO) Anadys (ANDS) Telaprevir Idenix (IDIX) Biogen Idec (BIIB) ImmunoGen (IMGN) Cytokinetics (CYTK) Sangamo (SGMO) Intercept (ICPT) Trastuzumab-DM1 SERES THERAPEUTICS (MCRB) KERYX (KERX) Onyx (ONXX) CompuGen (CGEN) Seattle Genetics (SGEN) REGULUS (RGLS) Aimmune Therapeutics (AIMT) Global Cell Therapeutics (GBT) Jazz Pharmaceuticals (JAZZ) Sanofi-Aventis (SAN) ARCA (ABIO) Benlysta (belimumab) Alder Biopharmaceuticals (ALDR) RenenxBio (RGNX) Human Longevity (HLI) Dynavax (DVAX) Theravance Bio Pharma (TBPH) TOKAI (TKAOI) IDERA (IDRA) Array Pharmaceuticals (ARRY) Inovio (INO) Genentech OSI (OSIP) Theravance (THRX) Prolor Biotech (PBTH) NEKTAR (NKTR)) Elan (ELN) ZALTRAP™ Intrexon (XON) Sanofi (SNA) ABBVIE (ABBV) C4 Therapeutics SUNESIS PHARMACEUTICALS (SNSS) Xoma (XOMA) Sequenom (SQNM) Ionis (IONS) Spike Therapeutics (ONCE) Agenus (AGEN Agenus (AGEN) Zerenex Revlimid (lenolidamide) Bristol-Myers Squibb (BMY) Alnylam (ALNY) Vertex (VRTX) INNOVIVA (INVA) AERIE PHARMACEUTICALS Multiple Myeloma Roche (RHHBY) Editas (EDIT) Intermune (ITMN) Human Genome Sciences (HGSI) Tysabri Dendreon (DNDN) Abbott Laboratories (ABT) HALOZYME (HALO) KITE (KITE) BIOMARIN (BMRN) Velcade (bortezomib) Incyte (INCY) GUARDIAN HEALTH Illumina (ILMN) AGOS (ARGS) Roche (ROCHE) Exelixis (EXEL) Prosensa (RNA) Micromet (MITI) VANDA (VNDA) GlaxoSmithKline (GSK) PTC Therapeutics (PTCT) ADVENTRIX (ANX) Amgen (AMGN) Endometrial Cancer Ariad (ARIA) Sanofi (SNY) Gilead (GILD) ISIS (ISIS) Sarepta (SRPT) ACADIA (ACAD) Anacor (ANAC) Pluristem (PSTI) Merck (MRK)